{
    "clinical_study": {
        "@rank": "20032", 
        "arm_group": {
            "arm_group_label": "Rivipansel/Placebo/Moxifloxacin", 
            "arm_group_type": "Experimental", 
            "description": "Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose"
        }, 
        "brief_summary": {
            "textblock": "This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of\n      GMI-1070 in African-American Adult subjects.  This is conducted as part of standard drug\n      development."
        }, 
        "brief_title": "A Study to Evaluate the Effect of IV Doses of Gmi-1070 on Qtc Intervals in Healthy African-American Adult Subjects", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Safety"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy African-American male and/or female subjects of non-childbearing potential\n             between the ages of 18 and 55 years, inclusive.\n\n        Exclusion Criteria:\n\n          -  Pregnant females; breastfeeding females; and females of childbearing potential. Males\n             who are unwilling or unable to use 2 highly effective method of contraception for the\n             duration of the study starting at least 14 days prior to the first dose of\n             investigational product and for at least 28 days after the last dose of\n             investigational product.\n\n          -  Non African-American.\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated,\n             asymptomatic,seasonal allergies at the time of dosing)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941511", 
            "org_study_id": "B5201001", 
            "secondary_id": "B5201001"
        }, 
        "intervention": {
            "arm_group_label": "Rivipansel/Placebo/Moxifloxacin", 
            "description": "Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.", 
            "intervention_name": "Rivipansel", 
            "intervention_type": "Drug", 
            "other_name": "GMI-1070"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "QTc", 
            "African-American", 
            "GMI-1070", 
            "QT/QTc interval prolongation"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5201001&StudyName=A%20Study%20to%20Evaluate%20the%20Effect%20of%20IV%20Doses%20of%20Gmi-1070%20on%20Qtc%20Intervals%20in%20Healthy%20African-American%20Adult%20Subjects%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Randomized, 3-way, Crossover Single Dose, Placebo, and Active Controlled Study to Evaluate the Effect of Intravenous Doses of Gmi-1070 on Qtc Intervals in Healthy African-American Adult Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "QTc, using Fridericia's correction method (QTcF) at each time point during rivipansel treatment period.", 
                "measure": "QTc, during rivipansel treatment period", 
                "safety_issue": "Yes", 
                "time_frame": "prior to dose, through 72 hours after dosing"
            }, 
            {
                "description": "QTc, using Fridericia's correction method (QTcF) at each time point during placebo treatment period.", 
                "measure": "QTc, during  placebo treatment period", 
                "safety_issue": "Yes", 
                "time_frame": "prior to dose, through 72 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941511"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "QTcF, or any other appropriate correction method at each postdose time point of moxifloxacin treatment.", 
            "measure": "QTc,  during moxifloxacin treatment period", 
            "safety_issue": "Yes", 
            "time_frame": "prior to dose, through 72 hours after dosing"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}